Persistence with anticoagulation for atrial fibrillation: Report from the gloria-af phase iii 1-year follow-up

the GLORIA-AF Investigators

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Background: We aimed to assess the extent to which drug persistence is better with non-vitamin K antagonist oral anticoagulants (NOACs) than vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients and to estimate the difference in therapy persistence depending on NOAC dosing regimen (once daily (QD) vs. twice daily (BID)). Methods: Consecutive patients were followed for 1 year in phase III of the GLORIA-AF registry. Drug persistence was defined as the use of OAC without any discontinuation in >30 days or switching to alternative therapy. Results: Among 21,109 eligible patients in phase III, 17,266 patients who were prescribed OAC at baseline and those who took ≥1 OAC dose were included. The 1-year proportion of patients receiving NOAC and VKA who persisted on treatment was 80% and 75%, respectively. The 1-year persistence with NOACs.

Original languageEnglish
Article number1969
Pages (from-to)1-11
Number of pages11
JournalJournal of Clinical Medicine
Volume9
Issue number6
DOIs
StatePublished - Jun 2020

Fingerprint

Dive into the research topics of 'Persistence with anticoagulation for atrial fibrillation: Report from the gloria-af phase iii 1-year follow-up'. Together they form a unique fingerprint.

Cite this